Menu
Not yet recruiting NCT07170059

Observational Study on the Impact of Herpes Zoster Vaccine on the Incidence of Herpes Zoster and Survival in Lung Cancer Patients

— Observational Lung Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: herpes zoster vaccine.
Who it may be relevant to
Registry conditions: Lung Cancer. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

An Observational Study on the Impact of Herpes Zoster Vaccine on the Incidence of Herpes Zoster and Survival in Lung Cancer Patients

Overview

To evaluate the impact of herpes zoster vaccine on the incidence of herpes zoster and survival in lung cancer patients, and to explore its preventive effect and safety.

Interventions

  • Biological herpes zoster vaccine
    Receive the herpes zoster vaccine; Do not receive the herpes zoster vaccine

Primary outcome measures

  • The incidence of herpes zoster at 12 months [Time frame: 12 months]
  • Incidence of herpes zoster [Time frame: 24 months]
Secondary outcome measures (1)
  • Survival rate [Time frame: 5 years]

Eligibility criteria

Inclusion criteria

  • 1.Male or female patients >=18 years of age; 2.Histological diagnosis of NSCLC, including both non-small cell lung cancer and small cell lung cancer, regardless of whether they are in the early, locally advanced stage or advanced stage, and regardless of whether they have received surgery, radiotherapy, chemotherapy or other treatments; 3. Never received herpes zoster vaccine

Exclusion criteria

  • Patients having other factors that preventing researchers from enrollment them.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07170059 · ZSHV-LC-OBS2025

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗